Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Post by jopatcloon Jun 22, 2024 7:34am
103 Views
Post# 36101337

👀Hugh and Hannah likes post Fantastic team work 👏

👀Hugh and Hannah likes post Fantastic team work 👏Interesting Hannah Crane and Hugh MacNaught likes post Fantastic team work
Hughs profile photo
Hugh MacNaught likes this
Petra Jenkins
Fantastic team work
Salim Jivanji
Arul Narayanan
Suneil Aggarwal
Hitesh Tailor
Liverpool Heart and Chest Hospital
The Adult Congenital Heart Disease Service Team were delighted to carry out their first SV-ASD/PAPVD stent implants at LHCH recently.

Two patients experiencing significant symptoms due to their Sinus Venosus ASD with partial Anomalous Pulmonary venous drainage, but who were unable to undergo heart surgery, were thrilled to be eligible for the custom-made stents.

As the second largest ACHD centre in the country, and one of only three centres in the UK able to provide this procedure, it was a significant achievement for the whole clinical team.

Dr Petra Jenkins, Consultant Cardiologist in Adult Congenital Heart Disease at LHCH, said: “The ACHD service in Liverpool has been established now for about 5 years and in that time we have become the second largest centre in the UK. We are taking on increasingly complex and state-of-the-art cases, adopting new innovations in congenital heart disease to improve overall patient care.

“As a collaborative multi-disciplinary team, we are definitely advancing innovation on a national basis and it gives us a huge sense of pride to be able to provide care and treatment to patients who previously were not considered eligible for surgery, due to increased risk or where post-operative recovery would prove to be challenging.

“The innovative procedure carried out, with custom-made stents due to the patients’ congenital heart issues, has been made possible thanks to the support and collaborative work undertaken with device manufacturers such as NuMED for Children. The result is that patients have a quick hospital stay and are able to go home the following day, without staying in ICU and a quick recovery.”

The clinical team was led by Dr Salim Jivanji, Consultant in Congenital Interventional Cardiology at Alder Hey and LHCH; Dr Arul Narayanan, Consultant in Congenital Interventional Cardiology at Alder Hey; Dr Suneil Aggarwal, Consultant Cardiologist in Adult Congenital Heart Disease at LHCH; and was supported on the day by Professor Eric Rosenthal, CHD Interventionist and Dr Saleha Kabir, lead echocardiographer from Evelina London Children’s Hospital, and Dr Petra Jenkins, ACHD Cardiologist. 

#congenitalheartdisease #ACHD #TeamLHCH

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities